share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Patel Naimish

SEC announcement ·  May 30 04:20
Summary by Futu AI
CRISPR Therapeutics AG's Chief Medical Officer, Patel Naimish, was involved in a transaction with the company's stock on May 28, 2024. However, the details of the transaction, including the action type, status, number of shares, nature of shares, transaction price, and total value of shares, have not been disclosed. The number of shares held by Patel Naimish after the transaction is also undisclosed. Investors are advised to await further information for a complete understanding of the transaction's impact on their investment decisions.
CRISPR Therapeutics AG's Chief Medical Officer, Patel Naimish, was involved in a transaction with the company's stock on May 28, 2024. However, the details of the transaction, including the action type, status, number of shares, nature of shares, transaction price, and total value of shares, have not been disclosed. The number of shares held by Patel Naimish after the transaction is also undisclosed. Investors are advised to await further information for a complete understanding of the transaction's impact on their investment decisions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.